BR112018007604A2 - métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk - Google Patents

métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk

Info

Publication number
BR112018007604A2
BR112018007604A2 BR112018007604-0A BR112018007604A BR112018007604A2 BR 112018007604 A2 BR112018007604 A2 BR 112018007604A2 BR 112018007604 A BR112018007604 A BR 112018007604A BR 112018007604 A2 BR112018007604 A2 BR 112018007604A2
Authority
BR
Brazil
Prior art keywords
pyrimidine
methods
treating cancer
pyridine compounds
inhibitory activity
Prior art date
Application number
BR112018007604-0A
Other languages
English (en)
Other versions
BR112018007604B1 (pt
Inventor
R. Huck Bayard
M. GOODSTAL Samantha
Gimmi-Mckim Claude
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112018007604A2 publication Critical patent/BR112018007604A2/pt
Publication of BR112018007604B1 publication Critical patent/BR112018007604B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

a presente invenção refere-se a métodos de tratamento de câncer usando compostos de pirimidina e piridina que são inibidores da tirosina quinase de bruton (btk).
BR112018007604-0A 2015-11-04 2016-11-04 Uso de compostos de pirimidina e piridina, e medicamentos BR112018007604B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US62/250,575 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US62/296,143 2016-02-17
US201662341189P 2016-05-25 2016-05-25
US62/341,189 2016-05-25
PCT/US2016/060508 WO2017079542A1 (en) 2015-11-04 2016-11-04 Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (2)

Publication Number Publication Date
BR112018007604A2 true BR112018007604A2 (pt) 2018-10-23
BR112018007604B1 BR112018007604B1 (pt) 2022-08-16

Family

ID=57442803

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007604-0A BR112018007604B1 (pt) 2015-11-04 2016-11-04 Uso de compostos de pirimidina e piridina, e medicamentos

Country Status (22)

Country Link
US (3) US20170119766A1 (pt)
EP (2) EP3371165B1 (pt)
JP (3) JP6913100B2 (pt)
KR (1) KR20180073599A (pt)
CN (1) CN108779095A (pt)
AU (3) AU2016349584B9 (pt)
BR (1) BR112018007604B1 (pt)
CA (1) CA3001735A1 (pt)
DK (1) DK3371165T3 (pt)
ES (1) ES2912059T3 (pt)
HU (1) HUE058323T2 (pt)
IL (2) IL293093B1 (pt)
LT (1) LT3371165T (pt)
MX (2) MX2018005461A (pt)
NZ (1) NZ741293A (pt)
PL (1) PL3371165T3 (pt)
RS (1) RS63146B1 (pt)
RU (2) RU2765154C2 (pt)
SG (2) SG10202005292UA (pt)
SI (1) SI3371165T1 (pt)
TW (2) TW202320784A (pt)
WO (1) WO2017079542A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ741293A (en) * 2015-11-04 2023-06-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
BR112018007517B1 (pt) * 2015-11-17 2023-09-26 Merck Patent Gmbh Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla
WO2018204532A1 (en) * 2017-05-03 2018-11-08 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019243223A1 (en) 2018-06-19 2019-12-26 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
US20210308140A1 (en) 2018-07-25 2021-10-07 Novartis Ag Nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
UY39377A (es) 2020-08-14 2022-03-31 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
TW202304889A (zh) * 2021-04-03 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 作為fgfr抑制劑的雜環化合物及其應用
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023247774A1 (en) 2022-06-24 2023-12-28 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
TW202406550A (zh) 2022-08-03 2024-02-16 瑞士商諾華公司 Ｎｌｒｐ３炎性小體抑制劑

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
TW520362B (en) * 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
EP2786995A1 (en) * 2004-03-30 2014-10-08 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
CL2009001152A1 (es) * 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
JP2014517016A (ja) * 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014151620A1 (en) * 2013-03-14 2014-09-25 Boehringer Ingelheim International Gmbh 5-thiazolecarboxamide dervatives and their use as btk inhibitors
MY184292A (en) * 2013-09-22 2021-03-30 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
GB201404987D0 (en) * 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
NZ741293A (en) * 2015-11-04 2023-06-30 Merck Patent Gmbh Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity
BR112018007517B1 (pt) * 2015-11-17 2023-09-26 Merck Patent Gmbh Uso decompostos de pirimidina e piridina com atividade inibidora de btk para preparar medicamentos para tratar esclerose múltipla

Also Published As

Publication number Publication date
RS63146B1 (sr) 2022-05-31
HUE058323T2 (hu) 2022-07-28
LT3371165T (lt) 2022-05-10
SG10202005292UA (en) 2020-07-29
US11491153B2 (en) 2022-11-08
IL293093A (en) 2022-07-01
KR20180073599A (ko) 2018-07-02
AU2021211982B2 (en) 2023-03-02
US20210244736A1 (en) 2021-08-12
JP7295169B2 (ja) 2023-06-20
IL258979A (en) 2018-06-28
TW202320784A (zh) 2023-06-01
CN108779095A (zh) 2018-11-09
RU2018120153A (ru) 2019-12-05
AU2021211982A1 (en) 2021-08-26
AU2016349584A1 (en) 2018-04-26
JP2021165308A (ja) 2021-10-14
MX2021015826A (es) 2022-02-03
EP3371165A1 (en) 2018-09-12
SG11201802927VA (en) 2018-05-30
RU2022100782A (ru) 2022-02-03
SI3371165T1 (sl) 2022-05-31
JP2018532805A (ja) 2018-11-08
MX2018005461A (es) 2018-08-01
NZ741293A (en) 2023-06-30
CA3001735A1 (en) 2017-05-11
WO2017079542A1 (en) 2017-05-11
AU2016349584B2 (en) 2021-05-13
TW201722430A (zh) 2017-07-01
EP3371165B1 (en) 2022-01-26
RU2018120153A3 (pt) 2020-03-05
IL258979B (en) 2022-06-01
AU2023203377A1 (en) 2023-06-29
AU2016349584B9 (en) 2021-06-03
JP6913100B2 (ja) 2021-08-04
JP2023105214A (ja) 2023-07-28
TWI783915B (zh) 2022-11-21
RU2765154C2 (ru) 2022-01-26
IL293093B1 (en) 2024-03-01
EP4014977A1 (en) 2022-06-22
US20170119766A1 (en) 2017-05-04
DK3371165T3 (da) 2022-05-02
ES2912059T3 (es) 2022-05-24
PL3371165T3 (pl) 2022-05-02
US20200206224A1 (en) 2020-07-02
BR112018007604B1 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
BR112018007604A2 (pt) métodos para tratar câncer usando compostos de pirimidina e piridina com atividade inibitória de btk
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
CO2017012947A2 (es) Inhibidores de tirosina-cinasas
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
ECSP17003553A (es) Compuestos de heteroarilo para la inhibición de cinasa
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
BR112017025986A2 (pt) inibidores de tirosina quinase de bruton.
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
EA201891626A1 (ru) Ингибиторы тирозинкиназы брутона
CL2015001990A1 (es) Compuestos de pirrolopirimidina substituidos, composiciones de los mismos, y métodos de tratamiento con los mismos.
BR112018011709A2 (pt) inibidores bicíclicos de pad4
BR112017020743A2 (pt) cocristais de um inibidor da tirosina cinase de bruton.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
BR112017022281A2 (pt) métodos para tratar câncer
BR112015019624A2 (pt) quinazolinas como inibidores de quinase
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
NZ740817A (en) Pcna inhibitors
BR112017018183A2 (pt) derivados de pirimidina como inibidores de quinase e suas aplicações terapêuticas.
BR112018012341A2 (pt) compostos úteis como inibidores da quinase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/11/2016, OBSERVADAS AS CONDICOES LEGAIS